China, India and Japan lead the adoption rate.
The Asia Pacific (APAC) companion diagnostics market is expected to reach $2.84b by 2033, growing at a CAGR of 14.53% between 2023 and 2033, driven by the rise of personalized treatments and chronic diseases.
According to ResearchAndMarkets.com, the companion diagnostics market is valued at $733.7 million in 2023 and is growing due to increased approvals, advanced imaging, and rising cancer rates. This is driving the adoption of precision medicine and companion diagnostics for personalized cancer treatment in Asia Pacific.
The market is driven by technological developments in assay development and biomarker discovery, in addition to the increasing adoption of personalized treatments and rise in chronic diseases.
“Thanks to advances in genomic and molecular testing technologies, the discovery of biomarkers associated with a variety of diseases has made it easier to develop customized treatments. In addition, an encouraging legal framework and pharmaceutical companies providing more funding for R&D have Contribute to market expansion,” the report stated.
China, India and Japan lead the way in the adoption of companion diagnostics.
